Hi all, Regarding the clinic data of MSBB database (https://www.synapse.org/#!Synapse:syn6101474), for NP.1 column, how to decide whether the samples with 3 and 4 values AD or not in general. Thanks

Created by Min Tang boymin2020

Hi, I would like to know which are the scores of CDR and Braak that define a patient as AD or Control. This information is not entire clear to me. Cheers, Lukas Iohan
@minghui.wang Thanks a lot!
The classification was based on CDR, with controls (CDR = 0), MCI (CDR = 0.5) and AD (CDR > 0.5).
Hi @minghui.wang I have noticed that in your Scientific Data paper, table 2 shows there are 40 Controls, 43 MCIs, 258 ADs and 8 Unclassified. However there are no definitions of these groups in the paper. I'd like to know the criteria of seperating samples into groups. Thanks!
Hi @minghui.wang @ben.logsdon, I have another question about the MSBB covariates. I have checked the ApoE information in the clinical file https://www.synapse.org/#!Synapse:syn6101474 (MSBB_clinical.csv), there are near 42% individuals missing ApoE information. Do you have an update about the file? Bests
@ben.logsdon @minghui.wang Thanks for your answers.
Ben's answer is correct. The MSBB AD cohort contains samples with a full spectrum of disease neuropathology and clinical outcomes. I wouldn't recommend treating the MSSB samples as simply AD or control. Minghui
Hi @boymin2020, I believe that NP.1 indicates the CERAD score of the individual, which is a measure of amyloid pathology. @minghui.wang is that correct? Generally speaking NP.1, NFT, and clinical diagnosis (e.g. CDR) are combined to determine a diagnosis of AD. Ben

Diagnosis based on clinic data in MSBB page is loading…